Balchem Corp: Form 10-K for the period ended Dec 31, 2022
Filed with the SEC on Feb 24, 2023 and accepted by EDGAR at Feb 24, 2023, 16:43 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-10-01 to 2022-12-31 | $232.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2022-01-01 to 2022-12-31 | $942.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2022-01-01 to 2022-12-31 | $661.9m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2022-10-01 to 2022-12-31 | $68.6m | us-gaap:GrossProfit |
| Gross profit | 12 months2022-01-01 to 2022-12-31 | $280.5m | us-gaap:GrossProfit |
| Research and development | 12 months2022-01-01 to 2022-12-31 | $12.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2022-01-01 to 2022-12-31 | $145.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2022-01-01 to 2022-12-31 | $28.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-10-01 to 2022-12-31 | $21.4m | us-gaap:NetIncomeLoss |
| Net income | 12 months2022-01-01 to 2022-12-31 | $105.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-10-01 to 2022-12-31 | $0.66 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2022-01-01 to 2022-12-31 | $3.25 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-10-01 to 2022-12-31 | $0.67 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | $3.29 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2022-01-01 to 2022-12-31 | 32,393,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | $138.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $49.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2022-01-01 to 2022-12-31 | $20.7m | us-gaap:PaymentsOfDividends |
| Share repurchases | 12 months2022-01-01 to 2022-12-31 | $35.4m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-12-31 | $66.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $335.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $1.62bn | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $140.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $686.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-12-31 | $938.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-23-005074. Last ingested by Listed: Oct 24, 2026, 14:51 ET. Listed shows no prices and gives no investment advice.